Cognoptix to focus on early Alzheimer's diagnosis at the point of care
At the 9th Annual Lux Executive Summit: Seizing the Innovation Initiative (Boston, MA) event held on March 31, 2014, Cognoptix (Acton, MA) president and CEO Paul Hartung told a group of analysts that the company's “...vision is to change the course of Alzheimer’s disease by enabling early diagnosis at the point of care.”
Related: Optics and photonics enable point-of-care solutions
To that end, the company published strong results from a multisite clinical trial of its SAPPHIRE II eye test, which identifies Alzheimer’s disease patients via a beta-amyloid (Ab) signature in their eyes, in the peer-reviewed Journal of Alzheimer’s Disease & Other Dementias (AJA) in February 2014.
“We have made great progress, ” Hartung added, “in developing an early-stage, noninvasive diagnostic test for AD designed to allow treatment to start before significant neuronal loss and irreversible brain damage occur.”
Hartung has closed Seed, Series A, Series B, and Series C financing rounds for the company, totaling $17 million with an international Angel and VC syndicate.
For more information, please visit http://dx.doi.org/10.1177/1533317513520214.
-----
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!